FTRK
Fast Track Group NASDAQ Listed May 23, 2025$1.30
+0.00%
vs $1.30
Mkt Cap $22.8M
52w Low $0.12
30.5% of range
52w High $4.00
50d MA $0.70
200d MA $0.59
P/E (TTM)
-3.5x
EV/EBITDA
—
P/B
—
Debt/Equity
-0.0x
ROE
-2.8%
P/FCF
53.4x
RSI (14)
56.00
ATR (14)
$0.46
Beta
-4.38
50d MA
$0.70
200d MA
$0.59
Avg Volume
339.5K
Fast Track Group provides entertainment-focused event management and marketing services in Singapore, Malaysia, and Thailand. The company operates through Live Entertainment and Agency segments. It engages in the organization and management of live events and concerts by renowned international artistes. The company also provides agency services for artiste endorsements, including artiste broker and supply services to clients. In addition, it offers media planning, public relations management, technical production planning, celebrity sourcing, celebrity engagement consultancy, and event manpower support services. The company was incorporated in 2012 and is based in Singapore.
No. 04-01, 12 Mohamed Sultan Road · Singapore 238961 · SG
No earnings history available.
No analyst ratings available.
No insider trades available.
8-K · 8.01
!! High
Azitra, Inc. -- 8-K 8.01: Material Event / Announcement
Oct 1
8-K · 2.02
!! High
BlossomHill Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Sep 18
8-K · 8.01
!! High
NRx Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Sep 16
8-K
Coya Therapeutics, Inc. -- 8-K Filing
Sep 15
8-K · 7.01
! Medium
Jazz Pharmaceuticals plc -- 8-K 7.01: Regulation FD Disclosure
Sep 15
8-K · 7.01
! Medium
BlossomHill Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Sep 15
8-K · 7.01
! Medium
Armata Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Sep 14
8-K · 7.01
! Medium
Incannex Healthcare Limited -- 8-K 7.01: Regulation FD Disclosure
Sep 9
8-K · 7.01
! Medium
Azitra, Inc. -- 8-K 7.01: Regulation FD Disclosure
Sep 8
8-K · 8.01
!! High
Liquidia Corporation -- 8-K 8.01: Material Event / Announcement
Sep 3
8-K · 7.01
! Medium
uniQure N.V. -- 8-K 7.01: Regulation FD Disclosure
Sep 2
8-K
PMV Pharmaceuticals, Inc. -- 8-K Filing
Aug 31
8-K · 7.01
! Medium
Incannex Healthcare Limited -- 8-K 7.01: Regulation FD Disclosure
Aug 25
8-K · 8.01
!! High
Erasca, Inc. -- 8-K 8.01: Material Event / Announcement
Aug 24
8-K · 8.01
!! High
Oncolytics Biotech Inc. -- 8-K 8.01: Material Event / Announcement
Aug 18
8-K
Allogene Therapeutics, Inc. -- 8-K Filing
Aug 12
8-K · 2.02
!! High
Arbutus Biopharma Corporation -- 8-K 2.02: Earnings Results
Aug 12
8-K · 2.02
!! High
Altimmune, Inc. -- 8-K 2.02: Earnings Results
Aug 12
8-K · 2.02
!! High
Coya Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Aug 11
8-K
Hemab Therapeutics Holdings, Inc. -- 8-K Filing
Aug 11
8-K · 7.01
! Medium
Jazz Pharmaceuticals plc -- 8-K 7.01: Regulation FD Disclosure
Aug 10
8-K · 2.02
!! High
Palvella Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Aug 4
8-K
DXC Technology Company -- 8-K Filing
Jul 30
8-K · 7.01
! Medium
Incannex Healthcare Limited -- 8-K 7.01: Regulation FD Disclosure
Jul 23
8-K · 7.01
! Medium
Monopar Therapeutics Inc. -- 8-K 7.01: Regulation FD Disclosure
Jul 22
8-K · 8.01
!! High
Oncolytics Biotech Inc. -- 8-K 8.01: Material Event / Announcement
Oncolytics Biotech received FDA approval for Pelareorep treating previously-treated anal squamous cell carcinoma, expanding the company's commercial opportunities in oncology.
Jul 20
8-K · 8.01
!! High
Oncolytics Biotech Inc. -- 8-K 8.01: Material Event / Announcement
Oncolytics Biotech scheduled a Type D FDA meeting to discuss registrational expansion plans, potentially accelerating its path toward broader clinical development and future regulatory approval.
Jul 13
8-K · 7.01
! Medium
Incannex Healthcare Limited -- 8-K 7.01: Regulation FD Disclosure
Jun 25
8-K · 7.01
! Medium
Neonc Technologies Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
NeOnc Technologies Holdings disclosed material information via press release on June 23, 2026, requiring investors to review the furnished exhibit for details on the company announcement.
Jun 23
8-K · 8.01
!! High
Armata Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 23
8-K · 8.01
!! High
Oncolytics Biotech Inc. -- 8-K 8.01: Material Event / Announcement
Jun 16
8-K · 8.01
!! High
Inhibrx Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Inhibrx Biosciences' ozekibart has cleared FDA acceptance for a BLA in unresectable/metastatic chondrosarcoma with an April 2027 decision deadline, supporting potential near-term approval and commercialization catalyst.
Jun 15
8-K · 8.01
!! High
Incyte Corporation -- 8-K 8.01: Material Event / Announcement
Jun 8
8-K · 8.01
!! High
INmune Bio, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 2
8-K · 8.01
!! High
NRx Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 2
8-K · 8.01
!! High
Oncolytics Biotech Inc. -- 8-K 8.01: Material Event / Announcement
Jun 1
8-K · 7.01
! Medium
Incannex Healthcare Limited -- 8-K 7.01: Regulation FD Disclosure
May 14
8-K · 2.02
!! High
Dogwood Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Dogwood Therapeutics disclosed financial results via 8-K filing, requiring investors to review the attached press release for details on operational performance and financial condition changes.
May 14
8-K · 2.02
!! High
Cypherpunk Technologies Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 2.02
!! High
Arbutus Biopharma Corporation -- 8-K 2.02: Earnings Results
May 13
8-K · 2.02
!! High
Corbus Pharmaceuticals Holdings, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 8.01
!! High
Coya Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
May 12
8-K · 2.02
!! High
Climb Bio, Inc. -- 8-K 2.02: Earnings Results
Climb Bio reported earnings results via press release, though specific financial metrics aren't detailed in this filing summary, so investors should review the attached exhibit for performance details and guidance.
May 7
8-K · 2.02
!! High
Amylyx Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Amylyx Pharmaceuticals disclosed quarterly earnings results via 8-K filing, with detailed financial performance metrics available in the attached press release exhibit for investor review.
May 7
8-K · 2.02
!! High
Cadrenal Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Cadrenal Therapeutics reported Q1 2026 financial results on May 7, 2026, which investors can review in the accompanying press release for operational performance and cash position details.
May 7
8-K · 2.02
!! High
Generate Biomedicines, Inc. -- 8-K 2.02: Earnings Results
Generate Biomedicines reported Q1 2026 financial results, providing investors with updated performance metrics on revenue, expenses, and cash position for the quarter ending March 31, 2026.
May 7
8-K · 2.02
!! High
Lipocine Inc. -- 8-K 2.02: Earnings Results
Lipocine Inc. reported Q1 2026 financial results, with investors now able to assess the biotech company's operational progress and cash burn rate through March 31.
May 7
8-K · 8.01
!! High
Allarity Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Allarity Therapeutics disclosed a material announcement via press release but the 8-K filing does not specify the announcement's content, leaving investors without concrete details on the reported event.
May 6
8-K · 2.02
!! High
Precision BioSciences, Inc. -- 8-K 2.02: Earnings Results
Precision BioSciences reported earnings results via 8-K filing, with complete financial details available in the attached press release exhibit for investors analyzing DTIL/FTRK performance.
May 5
8-K · 7.01
! Medium
Climb Bio, Inc. -- 8-K 7.01: Regulation FD Disclosure
Climb Bio disclosed investor event materials via webcast, indicating the company is providing strategic updates to shareholders through formal disclosure channels.
May 5
Institutional (13F) — Top 3
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 60,836 | $27K | New | Jun 2026 |
| 2 | Susquehanna International Group, Llp | 34,419 | $14K | New | Mar 2026 |
| 3 | Ubs Group Ag | 15,159 | $6K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$22.8M
Enterprise Value
$22.5M
P/E (TTM)
-3.50x
Forward P/E
—
PEG Ratio
0.12x
P/B
—
P/S
7.28x
P/FCF
53.37x
EV/EBITDA
—
Shares Out
17.5M
Financials (TTM)
Revenue
$3.1M
Net Income
-$8.2M
EBITDA
-$8.2M
Free Cash Flow
$426K
Op Cash Flow
$428K
EPS Basic
$-0.03
EPS Diluted
$-0.37
EPS Forward
—
Gross Margin
33.3%
Op Margin
-268.8%
Net Margin
-261.7%
Balance Sheet
Total Assets
$1.4M
Total Liab.
$2.6M
Total Equity
-$1.2M
Cash
$268K
LT Debt
$0
Book Value/Sh
$-0.07
Debt/Equity
-0.02x
Current Ratio
0.58
Quick Ratio
0.58
Returns & Growth
ROE
-2.8%
ROA
-2.4%
ROIC
47.3%
Rev Growth YoY
-21.5%
EPS Growth YoY
-1463.2%
Price Returns
2W
+132.1%
1M
-44.1%
3M
-64.3%
6M
-74.8%
12M
-75.3%
Technicals
52W High
$4.00
52W Low
$0.12
50d MA
$0.70
200d MA
$0.59
RSI (14)
56.00
ATR (14)
$0.46
Beta
-4.38
Avg Volume
340K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 10:18am
· Source: financialmodelingprep.com